Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Kevin Bi(Broad Institute), Meng Xiao He(Broad Institute), Ziad Bakouny(Dana-Farber Cancer Institute), Abhay Kanodia(Broad Institute), Sara Napolitano(Broad Institute), Jingyi Wu(Broad Institute), Grace Grimaldi(Broad Institute), David A. Braun(Broad Institute), Michael S. Cuoco(Broad Institute), Angie Mayorga(Dana-Farber Cancer Institute), Laura DelloStritto(Dana-Farber Cancer Institute), Gabrielle Bouchard(Dana-Farber Cancer Institute), John A. Steinharter(Dana-Farber Cancer Institute), Alok K. Tewari(Harvard University), Natalie I. Vokes(Broad Institute), Erin Shannon(Broad Institute), Maxine Sun(Dana-Farber Cancer Institute), Jihye Park(Broad Institute), Steven L. Chang(Brigham and Women's Hospital), Bradley A. McGregor(Dana-Farber Cancer Institute), Rizwan Haq(Broad Institute), Thomas Denize(Brigham and Women's Hospital), Sabina Signoretti(Brigham and Women's Hospital), Jennifer L. Guerriero(Harvard University), Sébastien Vigneau(Broad Institute), Orit Rozenblatt–Rosen(Broad Institute), Asaf Rotem(Broad Institute), Aviv Regev(Broad Institute), Toni K. Choueiri(Harvard University), Eliezer M. Van Allen(Broad Institute)
Cancer Cell
March 12, 2021
Cited by 623Open Access
Full Text

Abstract


Related Papers